调强放疗联合高强度聚焦超声及内分泌治疗前列腺癌的效果

发布时间：2018-04-28 11:39

本文选题：前列腺癌 + 调强放疗　；参考：《广东医学》2017年04期

【摘要】：目的观察调强放疗联合高强度聚焦超声及内分泌治疗中晚期前列腺癌的临床疗效及不良反应。方法将60例中晚期前列腺癌患者分为两组,观察组(30例)为调强放疗加内分泌治疗基础上联合高强度聚焦超声,对照组(30例)为调强放疗加内分泌治疗。治疗结束后3个月,检测患者血清前列腺特异抗原(PSA)水平,观察近期疗效及不良反应;随访3年评价远期疗效和生存率。结果治疗后患者症状缓解率观察组和对照组分别为93.3%及70.0%(P0.05);血清PSA均较治疗前明显下降,观察组和对照组分别为(9.9±5.28)ng/m L及(14.1±7.04)ng/m L(P0.05)。近期疗效评价观察组和对照组有效率分别为83.3%及56.7%(P0.05);观察组急性膀胱刺激症状、局部皮肤反应略高于对照组,但差异无统计学意义(P0.05)。两组1、3年生存率分别为90.0%、60.0%和80.0%、43.3%,两组比较差异无统计学意义(P0.05)。结论调强放疗联合高强度聚焦超声及内分泌治疗中晚期前列腺癌安全性及耐受性良好,可提高近期疗效并改善症状,但两者联合未能提高患者的生存率。
[Abstract]:Objective to observe the clinical efficacy and adverse reactions of intensity modulated radiotherapy (IMRT) combined with high intensity focused ultrasound (HIFU) and endocrine in the treatment of advanced prostate cancer. Methods 60 patients with advanced prostate cancer were divided into two groups: the observation group (n = 30) received intensity modulated radiotherapy plus endocrine therapy combined with high intensity focused ultrasound, and the control group (n = 30) received intensity modulated radiotherapy plus endocrine therapy. The serum prostate specific antigen (PSAs) levels were measured at 3 months after treatment and the short-term efficacy and adverse reactions were observed and the long-term efficacy and survival rate were evaluated after 3 years follow-up. Results after treatment, the remission rate of symptoms in the observation group and the control group were 93.3% and 70.0%, respectively, and the serum PSA levels were significantly lower than those before the treatment. The observation group and the control group were respectively 9.9 卤5.28)ng/m L and 14.1 卤7.04)ng/m L, respectively. The effective rates of the observation group and the control group were 83.3% and 56.7%, respectively, and the acute bladder irritation symptoms in the observation group were slightly higher than those in the control group, but the difference was not statistically significant (P 0.05). The 1- and 3-year survival rates of the two groups were 90. 0% and 80. 0% respectively. The difference between the two groups was not statistically significant (P 0. 05). Conclusion Intensity-modulated radiotherapy combined with high-intensity focused ultrasound and endocrine therapy has good safety and tolerance in the treatment of advanced prostate cancer. It can improve the short-term curative effect and improve the symptoms, but the combination of the two can not improve the survival rate of patients with advanced prostate cancer.
【作者单位】：南通大学第二附属医院放疗科;南通大学第二附属医院超声刀室;
【分类号】：R737.25

【参考文献】